Last reviewed · How we verify
SARS-COV-2 VIRUS SPIKE PROTEIN
At a glance
| Generic name | SARS-COV-2 VIRUS SPIKE PROTEIN |
|---|---|
| Modality | Vaccine component |
| Phase | FDA-approved |
| First approval | 2021 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
- Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults (PHASE1)
- Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection (NA)
- Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults (PHASE1)
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-COV-2 VIRUS SPIKE PROTEIN CI brief — competitive landscape report
- SARS-COV-2 VIRUS SPIKE PROTEIN updates RSS · CI watch RSS